CLSD | Clearside Biomedical, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.8010 - 0.9298
52 Week Range	0.8010 - 2.1200
Beta	2.02
Implied Volatility	418.74%
IV Rank	13.96%
Day's Volume	942,545
Average Volume	720,395
Shares Outstanding	75,843,500
Market Cap	66,158,285
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-06-02

Valuation
Profitability
Growth
Health
P/E Ratio	-1.94
Forward P/E Ratio	N/A
EPS	-0.45
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	30
Country	USA
Website	CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CLSD's peers: CDTX, PNT, ORIC, LYRA, INBX, EPIX, SNSE, NXTC, NUVB, GRPH, MACK, GRCL, THRX, GLUE, DSGN, ERAS, EYEN, DRTS, OCUL, TNYA, INZY, GBIO, KRON, CCCC, EWTX

*Chart delayed

Analyzing fundamentals for CLSD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is on medium level and Health is frighteningly weak. For more detailed analysis please see CLSD Fundamentals page.

Watching at CLSD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CLSD Technicals page.